Skip to main content

Highlights

  1. 1
    Clinical lung cancer · 2024
    PMID: 39232917DOIFirst author13 citations
  2. 2
    Haematologica · 2022
    PMID: 35708136PMCID: PMC9425307DOISenior author21 citations
  3. 3
    Journal of comparative effectiveness research · 2025
    PMID: 41392951PMCID: PMC12711101DOISenior author5 citations

Publications

36 publications

Clinical research

2 studies

Active

1 study
  • PI
    Multidimensional Unmet Needs Assessments of Asian Patients with EGFR-mutated Lung Cancer at Meyer Cancer Center (NewYork-Presbyterian-Weill Cornell, Lower Manhattan, Brooklyn & Queens)
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
Completed & closed trials (1)
  • PI
    A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
    PHASE2 · Spectrum Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2023)
    NSCLC
    NCT03318939

External relationships

Advisory/Scientific Board Member

Rigel Pharmaceuticals, Inc.

Other Interest

AbbVie Inc. · Aptitude Health · EMD Serono, Inc. · IDEO · Janssen Biotech Inc. · Johnson & Johnson · Pfizer, Inc.

Other

MJH Life Sciences · Pfizer, Inc. · Regeneron Pharmaceuticals, Inc.